Semax
⚠️ Disclaimer: Semax is approved as a medicinal product only in Russia. Outside Russia, this product is For Research Use Only. Not for human administration or clinical therapy.
Basic Information
- CAS No.: 80714-61-0
- Amino acid sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), synthetic heptapeptide, stabilized analog of ACTH(4-10) fragment
- Molecular Formula: \(\boldsymbol{C_{37}H_{51}N_9O_{10}S}\)
- Molecular Weight: 813.93 g/mol
- Appearance: White to off-white lyophilized powder
- Solubility: Soluble in bacteriostatic water / sterile water
- Storage: Lyophilized powder stored at -20℃, protected from light. After reconstitution, refrigerate (2–8℃) and use promptly; avoid repeated freeze-thaw cycles.
Development Background
Semax was developed at the Institute of Molecular Genetics, Russian Academy of Sciences in the 1980s. It is approved in Russia as nasal drops for ischemic stroke recovery, cerebrovascular insufficiency and cognitive impairment. It is modified by adding the Pro-Gly-Pro tripeptide at the C-terminus of ACTH(4-7). This modification increases resistance to enzymatic degradation and extends stability. Unlike full-length ACTH, Semax has no steroidogenic / cortisol-stimulating activity, retaining only neurotrophic effects.
Mechanism of Action (Research Findings)
- Rapid upregulation of BDNF and NGF: Promotes neuroplasticity, neuron survival and synaptic repair.
- Monoamine modulation: Activates dopaminergic and serotonergic pathways, supporting focus, executive function and mental endurance.
- Neuroprotection: Reduces oxidative stress and hypoxic neuronal damage; anti-inflammatory effects in nervous tissue.
- Melanocortin receptor modulation: Supports brain tissue recovery after ischemia or brain injury.
- Inhibits enkephalinase: Preserves endogenous enkephalin activity.
Research Areas
- Neuroprotection & brain ischemia / stroke recovery research
- Nootropic study: memory, learning, attention and cognitive function
- Traumatic brain injury & hypoxia models
- Relief of mental fatigue and stress-related cognitive decline








评价
目前还没有评价